BGM
MLYS icon

Burkehill Global Management’s Mineralys Therapeutics MLYS Stock Holding History

Burkehill Global Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Hold
150,000
– – 0.15% 91
2026
Q1 		$4.06M Hold
150,000
– – 0.2% 86
2025
Q4 		$5.44M Hold
150,000
– – 0.36% 74
2025
Q3 		$5.69M Buy
+150,000
New +$3.24M 0.32% 79

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Burkehill Global Management's MLYS Position: Q2 2026 in Review

Burkehill Global Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 150,000 shares worth $4.05M. The position accounts for 0.15% of the portfolio, ranked #91.

Burkehill Global Management first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.69M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Burkehill Global Management held 150,000 shares of Mineralys Therapeutics worth $4.05M as of Q2 2026.
  • Burkehill Global Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up 0.15% of Burkehill Global Management's portfolio in Q2 2026, its #91 holding.
  • Burkehill Global Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Burkehill Global Management's Mineralys Therapeutics position peaked at $5.69M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.